TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20226502

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (Iri) 35 mg/m(2) and cisplatin (CP) 20 mg/m(2) with 45‐Gy pelvic irradiation
Number of subjects: 15
Study: 19213341

Group type: EXPERIMENTAL
Intervention: Integrative medical treatment plus prednisone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prednisone only (control group)
Number of subjects: 110
Study: 16860509

Group type: EXPERIMENTAL
Intervention: Warfarin plasma concentration monitoring
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Warfarin dosage and concentration correlation with INR
Number of subjects: 58
Study: 12673147

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to the lower leg muscles
Number of subjects: 20

Group type: COMPARATOR
Intervention: No NMES (motionless standing)
Number of subjects: 20
Study: 10816062

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (Ctr)
Number of subjects: 37
Study: 8800634

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Two or more AEDs
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Vigabatrin and one other AED
Number of subjects: 923
Study: 1457271

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study: 6319449

Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 8
Study: 30446494

Group type: EXPERIMENTAL
Intervention: Genomic alterations (copy-number aberrations and copy-neutral loss of heterozygosity) identified by chromosome genomic-array testing (CGAT) at FL diagnosis
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 2p gain
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 2p cnLOH
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 2p gain encompassing VRK2 and FANCL
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CDKN2A/B (9p) deletion
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CREBBP (16p) deletion
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: TP53 (17p) deletion
Number of subjects: 255
Study: 29940217

Group type: EXPERIMENTAL
Intervention: BNX-RDT 11.4/2.9 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: BNX-RDT 2.9/0.71 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: BNX-RDT
Number of subjects: 125
Study: 27050599

Group type: EXPERIMENTAL
Intervention: Prospective group (CAO/ARO/AIO-04 trial)
Number of subjects: 479

Group type: COMPARATOR
Intervention: CAO/ARO/AIO-94 cohort
Number of subjects: 479
Study: 24387594

Group type: EXPERIMENTAL
Intervention: Health care ethics consultation (HCEC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62
Study: 21962726

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment (BT)
Number of subjects: 378
Study: 20157652

Group type: EXPERIMENTAL
Intervention: Panavia 21 (P21)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Super Bond C&B (SB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemiace II (CH)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Roughened dentinal walls (all cements)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Storage for 150 days with thermal cycling and mechanical loading
Number of subjects: 96
Study: 17658977

Group type: EXPERIMENTAL
Intervention: Lower levels of physical punishment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher levels of child-reported parental warmth and involvement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lower levels of anxiety
Number of subjects: 120
Study: 16125499

Group type: EXPERIMENTAL
Intervention: Candesartan or enalapril or both (specific dosages and duration not mentioned)
Number of subjects: 768
Study: 11831838

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg once daily
Number of subjects: 15
Study: 10399370

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Guanosine 5'-monophosphate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 18
Study: 7494939

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 1553897

Group type: EXPERIMENTAL
Intervention: Regimen A: metoclopramide [2 mg/kg x 4 i.v.] + methylprednisolone (250 mg x 2 i.v.) + diphenhydramine (50 mg x 2 i.v.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen B: metoclopramide (3 mg/kg x 2 i.v.) + dexamethasone (20 mg i.v.) + diphenhydramine (50 mg i.v.)
Number of subjects: 32
Study: 3898413

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31126825

Group type: EXPERIMENTAL
Intervention: SMART intervention (8-week program)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist control (WL) followed by SMART intervention
Number of subjects: 102
Study: 29587875

Group type: EXPERIMENTAL
Intervention: Microlife® CRADLE Vital Sign Alert (VSA) device and CRADLE training package
Number of subjects: 10

Group type: COMPARATOR
Intervention: Routine maternity care
Number of subjects: 10
Study: 30230756

Group type: EXPERIMENTAL
Intervention: Propranolol + Candesartan
Number of subjects: 75

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 75
Study: 25528622

Group type: EXPERIMENTAL
Intervention: Reamed locked intramedullary nailing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Biplanar external fixation
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using SF-36 Health Survey
Number of subjects: 68
Study: 22647889

Group type: EXPERIMENTAL
Intervention: Combined simvastatin and ezetimibe treatment
Number of subjects: 1616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616
Study: 20501862

Group type: EXPERIMENTAL
Intervention: Isotretinoin (30 mg/d for 3 years)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1166
Study: 18344886

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 10

Group type: COMPARATOR
Intervention: Infliximab and Placebo
Number of subjects: 10
Study: 16538734

Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 6 +/- 2 mg/kg
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 15 +/- 2 mg/kg
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 24 +/- 2 mg/kg
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Iodized salt with iodine concentration of 34 +/- 2 mg/kg
Number of subjects: 1099
Study: 12434280

Group type: EXPERIMENTAL
Intervention: Cisplatin/epinephrine gel
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 92
Study: 9580075

Group type: EXPERIMENTAL
Intervention: Butantan polyspecific, pepsin‐digested Bothrops antivenom (Group A)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Butantan polyspecific, whole IgG Bothrops antivenom (Group B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Colombian commercial, monovalent, whole IgG Bothrops antivenom (Group C)
Number of subjects: 79

Group type: COMPARATOR
Intervention: All antivenoms
Number of subjects: 79
Study: 7822630

Group type: EXPERIMENTAL
Intervention: School-based tic assessment procedure (direct observations, teacher rating scales)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct observations of tics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teacher rating scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall rates of hyperactive/disruptive behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral symptoms of both disorders
Number of subjects: 0
Study: 3046638

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n1 (Wellferon) intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Observation for six months
Number of subjects: 66
Study: 31784704

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Threshold conventional laser (TCL)
Number of subjects: 88
Study: 30526678

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (TNFi-naïve)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (TNFi-naïve)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (TNFi-naïve)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (TNFi-experienced)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (TNFi-experienced)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (TNFi-experienced)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study: 28356129

Group type: EXPERIMENTAL
Intervention: 6 g/d probiotic
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 6 g/d synbiotic
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25767411

Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 105
Study: 23650505

Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 198

Group type: COMPARATOR
Intervention: Gardasil®
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Cervarix® and Gardasil®
Number of subjects: 198
Study: 20587582

Group type: EXPERIMENTAL
Intervention: Persistent TSH-suppressive l-T4 substitution (low-TSH group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Restoration of euthyroidism
Number of subjects: 25

Group type: COMPARATOR
Intervention: Euthyroid controls
Number of subjects: 25
Study: 19431244

Group type: EXPERIMENTAL
Intervention: Cortexin, 20 mg daily for 10 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo, 20 mg daily for 10 days
Number of subjects: 62
Study: 16594814

Group type: EXPERIMENTAL
Intervention: 6 forms of a 6-month pharmaco-psychotherapy program
Number of subjects: 599
Study: 14644895

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT)
Number of subjects: 0
Study: 10878069

Group type: EXPERIMENTAL
Intervention: Cycle sequencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hybridization sequencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Population-based hybridization sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population cycle sequencing
Number of subjects: 0
Study: 9185371

Group type: EXPERIMENTAL
Intervention: Health education intervention in schools
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1689
Study: 8365196

Group type: EXPERIMENTAL
Intervention: Cost analysis of extending the duration of the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis of increasing the number of participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis of delay in accrual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost effectiveness of retention activities
Number of subjects: 0
Study: 2868294

Group type: EXPERIMENTAL
Intervention: Immunisation of the donor alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Immunisation of both donor and recipient
Number of subjects: 38
Study: 31674202

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing cranberry, D-mannose and anti-inflammatory molecules, taken twice a day for 2 weeks starting from surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgery only (Control)
Number of subjects: 40
Study: 29185674

Group type: EXPERIMENTAL
Intervention: ESWT+KT
Number of subjects: 42

Group type: COMPARATOR
Intervention: ESWT
Number of subjects: 42
Study: 27887579

Group type: EXPERIMENTAL
Intervention: levofloxacin (750 mg intravenous once daily for 7 days)
Number of subjects: 370

Group type: COMPARATOR
Intervention: ceftolozane/tazobactam (1.5 g intravenous every 8 h for 7 days)
Number of subjects: 370
Study: 24636796

Group type: EXPERIMENTAL
Intervention: Transtelephonic ECG system (TTECG)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Control group (no TTECG)
Number of subjects: 775
Study: 22417251

Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 182160

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 182160
Study: 20694783

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines administered according to syndrome typing for oral intake and external washing
Number of subjects: 76

Group type: COMPARATOR
Intervention: Glucosamine hydrochloride and Celecoxib, combined with intra-articular injection of sodium hyaluronate and peri-articular pain spot blocking with Triamcinolone Acetonaide Acetate injection
Number of subjects: 76
Study: 18279899

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) added to the soup during training sessions.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (soup unchanged, no MSG added).
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) paired with the soup during training.
Number of subjects: 32
Study: 16150070

Group type: EXPERIMENTAL
Intervention: Early case conferencing within 24 hours of admission
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard evaluation procedures (control)
Number of subjects: 25
Study: 12859160

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 10580945

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No CAD
Number of subjects: 146
Study: 8945035

Group type: EXPERIMENTAL
Intervention: Overlapping biphasic (OLBI) pacing at mid-RA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unipolar stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bipolar stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OLBI pacing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diaphragmatic pacing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrial pacing threshold on day 0 vs day 2
Number of subjects: 12
Study: 1681917

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g plus metronidazole 1.5 g once daily (n = 94)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ampicillin 2 g plus netilmicin 150 mg twice daily plus metronidazole 1.5 g once daily (n = 96)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ampicillin plus netilmicin plus metronidazole
Number of subjects: 190
Study: 7023519

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.02 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg kg‐1
Number of subjects: 60
Study: 31331027

Group type: EXPERIMENTAL
Intervention: Low-Protein (LP) formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher-Protein (HP) formula
Number of subjects: 0
Study: 27956248

Group type: EXPERIMENTAL
Intervention: Individualized cryoballoon (CB) pulmonary vein isolation (PVI) with no bonus freeze if TTI <75 seconds
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with acute PVI followed by 1 empiric bonus freeze
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individualized cryoballoon (CB) pulmonary vein isolation (PVI)
Number of subjects: 100
Study: 26898832

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study: 24637941

Group type: EXPERIMENTAL
Intervention: 400 mg t.i.d. sorafenib
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 600 mg b.i.d. sorafenib
Number of subjects: 41
Study: 21698556

Group type: EXPERIMENTAL
Intervention: Education (psycho-educational program)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Instruction (short instruction)
Number of subjects: 233
Study: 18094220

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg bid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg bid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid
Number of subjects: 18
Study: 16801665

Group type: EXPERIMENTAL
Intervention: Immunoablation and autologous hematopoietic stem cell transplantation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Analogous therapy in a patient with non‐CNS lymphoma
Number of subjects: 9
Study: 12972124

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biventricular pacemaker implantation
Number of subjects: 0
Study: 10751473

Group type: EXPERIMENTAL
Intervention: Imaging delay of 15 seconds
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Imaging delay of 25 seconds or later
Number of subjects: 75
Study: 8624887

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous hydrallazine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Number of subjects: 200
Study: 1419549

Group type: EXPERIMENTAL
Intervention: 500 mg cephradine 12-hourly for seven days
Number of subjects: 113

Group type: COMPARATOR
Intervention: 125 mg cefuroxime axetil 12-hourly for seven days
Number of subjects: 113
Study: 3973648

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) alone, 600 mg/m2 IV once weekly
Number of subjects: 148

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus radiation therapy, 4,000 rad, with adjuvant 5-FU, 600 mg/m2 IV for the first three days of radiotherapy, then maintenance 5-FU, 600 mg/m2 weekly
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 148

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus radiation therapy
Number of subjects: 148
Study: 31740072

Group type: COMPARATOR
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Robotic-Assisted Radical Cystectomy (RARC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic Radical Cystectomy (LRC)
Number of subjects: 60
Study: 29458423

Group type: EXPERIMENTAL
Intervention: Inspiring Futures parenting programme (group-based for 10-12 weeks and one-to-one for up to 12 weeks)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 248
Study: 28647736

Group type: EXPERIMENTAL
Intervention: 10 µg of vitamin D3 supplementation daily
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: 30 µg of vitamin D3 supplementation daily
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Both 10 µg and 30 µg of vitamin D3 supplementation
Number of subjects: 987
Study: 26427968

Group type: EXPERIMENTAL
Intervention: Timolol maleate applied topically together with propranolol given orally
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propranolol given orally
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Timolol maleate applied topically
Number of subjects: 39
Study: 23246368

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 36

Group type: COMPARATOR
Intervention: MenPS (control)
Number of subjects: 36
Study: 22013143

Group type: EXPERIMENTAL
Intervention: PGF2α (3.5 µg/kg/min over 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PGF2α
Number of subjects: 12
Study: 19485589

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with minimal parent involvement
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with active parent involvement
Number of subjects: 119
Study: 16996597

Group type: EXPERIMENTAL
Intervention: Nighttime systolic ABP
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Mean ABP
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nighttime to daytime APR ratio
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nondipper status
Number of subjects: 194
Study: 12957721

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study: 11204513

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9104900

Group type: EXPERIMENTAL
Intervention: Symptomatic patients (angina reported)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: History of angina within 6 weeks before randomization
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Angina during ambulatory electrocardiogram or stress test
Number of subjects: 558

Group type: COMPARATOR
Intervention: Asymptomatic patients (no angina reported)
Number of subjects: 558
Study: 1552888

Group type: EXPERIMENTAL
Intervention: Cefotiam (CTM-L group)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Cefotiam (CTM-H group)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Cefmenoxime (CMX-H group)
Number of subjects: 332
Study: 3553480

Group type: EXPERIMENTAL
Intervention: 1500 mg/day elemental calcium for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30149850

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 158
Study: 27093511

Group type: EXPERIMENTAL
Intervention: McGrath laryngoscope
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41